Gaps in moderate plaque psoriasis management: A survey of Saudi dermatologists

Mohammad Almohideb¹, Nora Abdulrahman Almohideb²

¹Department of Dermatology, King Saud bin Abdulaziz University for Health Sciences, College of Medicine, ²King Saud University Medical Intern, Riyadh, Saudi Arabia

ABSTRACT

Background: There are many barriers that usually lead to under-treatment of moderate psoriasis patients, with subsequent unsatisfactory results and clinical outcomes. Objective: Given this lack of consistent guidelines on treating moderate plaque psoriasis patients, the aim of the current study is to define how Saudi dermatologists define and treat such cases in the real-world clinical setting. Methods: We conducted an online cross-sectional survey from May 2020 to October 2020, involving all eligible dermatologists working at different academic, governmental, and private sectors in Saudi Arabia. Results: Finally, a total of 260 dermatologists were included in the final analysis; out of them, 140 (53.8%) were males and 120 (46.2%) were females. Regarding the tools used by participating dermatologists for diagnosis of moderate psoriasis, most of the participants (86.5%) used Body Surface Area (BSA), 7.3% used Physician Global Assessment (PGA), and 6.2% used Dermatology Life Quality Index (DLQI). Cutoff scores for defining moderate psoriasis varied widely among surveyed dermatologists. The surveyed dermatologists reported that 46% of their patients with moderate plaque psoriasis were receiving biologics as their primary therapy, while 24.1% were receiving prescription topical treatment, 20.3% were receiving an oral systemic therapy, 4.9% were using over-the-counter topical treatment, and 4.7% were receiving phototherapy. Conclusion: There is a pervasive lack of consensus regarding the definition of moderate psoriasis, with reported wide ranges among the commonly used severity tools in psoriasis patients.

Keywords: Dermatologists, disease severity, online survey, psoriasis, treatment

Introduction

There are many barriers that usually lead to under-treatment of moderate psoriasis patients, with subsequent unsatisfactory results and clinical outcomes.¹⁻⁸ Moreover, there is a lack of a consensus on the identification and appropriate treatment of moderate psoriasis patients. According to the American Academy of Dermatology (AAD), moderate psoriasis is identified when ≥5% to <10% of the body surface area (BSA) is affected by the disease.¹⁰ According to a European consensus, payer reimbursement criteria, and clinical trials; “the rule of ten” should be applied to define disease severity.¹¹⁻¹⁵ They define the mild disease when any/all of the following ≤10% affected percentage of BSA, Psoriasis Area and Severity Index [PASI], and/or Dermatology Life Quality Index [DLQI].¹⁶⁻¹⁹ When any of the three aforementioned parameters were higher than 10, the disease is classified as moderate to severe, with no separation of moderate and severe categories.¹⁶⁻¹⁹ Similarly, the US Food and Drug Administration (FDA) does not allow drug application for moderate psoriasis as a separate indication.¹¹ This comes in line with the absence of tailored treatment strategies for moderate psoriasis, which, in turn, the reason that many patients with moderate/moderate to severe diseases may end up receiving no treatments or topical ones, with no significant relief of symptoms.¹¹,²⁰

Based on the previously mentioned facts, there is a lack of necessary tools for doctors that would make it hard to make
informed decisions in terms of treatment and improving clinical outcomes. Based on the risk-benefit ratio, doctors may consider the conventional systemic or biological treatment inappropriate for the moderate form of psoriasis, with main concerns about the long-term side effects of such drugs.[5] Another drawback of the systemic treatments is the follow-up burden, where regular laboratory investigations and lifestyle adjustments are always needed.[12,13] Moreover, such treatment options may be unavailable to some patients due to cost concerns or insurance coverage issues, especially when coming to biologic treatment agents.[5]

A previous study, of 150 participants, examined how dermatologists define and manage moderate plaque psoriasis in actual clinical setting. The study confirmed the absence of a clear definition of moderate psoriasis among US dermatologists.[11] Given this lack of consistent guidelines on treating moderate plaque psoriasis patients, the aim of the current study is to define how Saudi dermatologists define and treat such cases in the real-world clinical setting.

Materials and Methods

Study design

This is an online cross-sectional survey that was conducted from May 2020 to October 2020, involving all eligible dermatologists working at different academic, governmental, and private sectors in Saudi Arabia.

Data collection

The survey questionnaire was prepared after a thorough review of the literature. The questions were customized to fit into the criteria of this study. The questionnaire's content was then validated by a panel of subject experts. A pilot study was conducted among 30 participants, who were not included in the final survey. The survey was analyzed using Cronbach's reliability coefficient. If there is any need, the needed changes were incorporated before using for the larger sample.

The questionnaire was composed of three parts: “Part A” that was the sociodemographic details and background clinical experience, “Part B” that assessed diagnosis and experience of moderate plaque psoriasis and “Part C” that assessed the treatment of moderate plaque psoriasis. The questionnaire was distributed online using Google forms. Only completely filled questionnaires were considered for the study.

Informed consent and ethical considerations

No identifying information of any participant was published and all collected data were exclusively used for statistical analysis. The data of the patients were kept confidentially. Every participant was asked to fill an online informed consent in the first page of the survey before being able to move further.

Statistical analysis

Data will be analyzed by SPSS 26 (SPSS Inc, Chicago, IL, USA). Descriptive statistics were calculated for all variables. For categorical variables, comparative analyses were carried out by Chi-square test or Fisher's exact test, as appropriate. Based on normality status, independent-samples t-test or Mann–Whitney U test is to compare females to males. A P value < 0.05 will be selected as a statistically significant level in all the tests.

Results

Respondent dermatologists

Finally, a total of 260 dermatologists were included in the final analysis; out of them, 140 (53.8%) were males and 120 (46.2%) were females. Dermatologists had a mean age of 36.9 ± 8.6 years and spent a mean of 9.4 ± 7.7 years in practice. One-third (36.2%) of the participants are currently working in a multi-specialty practice, 19.6% are currently working in a single-specialty practice, and 17.7% are currently working in a primary hospital. Respondent dermatologists spent an average of 41.5%, 37.1%, 34.1%, 31.3%, and 27.6% of their time working in direct patient care medical dermatology, surgical (non-cosmetic) dermatology, cosmetic dermatology, and dermato-pathology, respectively. There was a statistical significant difference between males and females in terms of dermatology certification (P value < 0.001), dermatology board eligibility (P value < 0.001), practice setting type (P value < 0.001), staff within practice (P value < 0.001), and time spent in different aspects of dermatology care (P value < 0.05). Sociodemographic data and background clinical experience are summarized in Table 1.

Diagnosis and experience of moderate plaque psoriasis

The participating dermatologists showed a reported variable number of examined psoriasis patients monthly; 31.5% examined <5 patients, 38.1% examined 10–20 patients, and 30.4% examined 20–40 patients. Nearly half of the participants (44.6%) reported the exacerbation of the disease as the main cause of dermatologic consultation among psoriasis patients, 28.1% of the patients coming for the first time, and 21.5% are coming as a regular visit. Regarding the encountered locations affected by psoriasis, dermatologists reported that 31.5% of the cases have affected feet, 14.6% have affected genital areas, 13.5% have affected faces, and 12.7% have affected scalps [Table 2].

The reported average percentage of mild psoriasis cases was 56.5%, while the moderate cases were 26.2%, and the severe cases were 17.3% [Figure 1]. Regarding the tools used by participating dermatologists for diagnosis of moderate psoriasis, most of the participants (86.5%) used Body Surface Area (BSA), 7.3% used Physician Global Assessment (PGA), and 6.2% used Dermatology Life Quality Index (DLQI). Cutoff scores for defining moderate psoriasis varied widely among surveyed dermatologists. Median low and high cutoffs for moderate psoriasis were 6% and 10% BSA, respectively; however, the minimum and maximum (min/max) range of BSA cutoffs used to define moderate psoriasis was very broad (overall min/max:
Treatment experience of moderate plaque psoriasis

The surveyed dermatologists reported that 46% of their patients with moderate plaque psoriasis were receiving biologics as their primary therapy, while 24.1% were receiving prescription topical treatment, 20.3% were receiving an oral systemic therapy, 4.9% were using over-the-counter topical treatment, and 4.7% were receiving phototherapy [Figure 3]. Regarding the duration of treatment, 36.9% of the participants reported giving treatment for 6 months, 30.0% reported giving it for 1 year, 18.5% were giving it for life, and 14.6% were giving it for only 3 months. About half of the respondents (50.4%) reported failure of treatment among 20%–40% of patients and reported impaired quality of life (52.7%) for psoriasis patients. Participants' treatment experience with moderate plaque psoriasis is summarized in Table 3.

Discussion

Patients with moderate plaque psoriasis represent an ill-defined segment of the psoriasis population. We conducted an online
cross-sectional survey involving 260 dermatologists working at different academic, governmental, and private sectors in Saudi Arabia. In the current study, most of the included dermatologists used BSA, where the median BSA for identifying moderate disease severity ranged from 6 to 10%, which was similar to the range of values suggested by a previous similar study and the AAD for moderate disease severity. Nevertheless, the range of BSA cutoff values were highly variable among dermatologists (1%–50%); similarly, wide ranges for moderate disease severity were reported by dermatologists on defining moderate psoriasis using other assessments (PGA and DLQI).

Although the majority of dermatologists used different scores to assess disease severity, they were also aware of different locations of the psoriasis lesions. The participants who considered the location of psoriasis lesions mentioned the feet, genital area, face, scalp, and legs as areas they use to determine psoriasis severity. These findings would recommend that dermatologists know that lesions in some areas may affect the patients’ quality of life and should be considered when determining disease severity or choosing the best treatment option. In the same context, the AAD urge dermatologists to consider lesions’ location when assessing the severity of psoriasis or determining the appropriate treatment strategy. Additionally, these findings would highlight the significance of considering new guidelines for defining moderate plaque psoriasis, with incorporating both the BSA score and the lesions’ location, which would have a potential impact on clinical practice.

The literature shows that patients may classify their disease as a higher severity than the one based on the BSA alone. In this regard, a multinational survey of 3426 patients showed that about half of the participants rated their disease as “moderate” or “severe,” while, based on BSA, their condition was mild ≤3%. Likewise, the clinical trials-derived evidence suggests that the patients’ quality of life, assessed by DLQI, is not conditionally related to the disease severity, as measured by BSA. In the ESTEEM I trial, of 844 patients, reported a DLQI score similar to the one reported by the UNVEIL trial; however, the former trial has three times higher BSA involvement (24%) compared to the latter trial (7%). In the current study, 6.2% of the surveyed dermatologists reported using the DLQI score in assessing...
psoriasis severity. That said, it is currently recommended by the National Psoriasis Foundation to assess the patient-reported outcomes (like quality of life and daily activities impairment) for a better determination of disease severity and selecting the best treatment option with further evaluation of its effectiveness.[10]

An interesting finding of the current survey is that 46.0% of dermatologists reported the use of biologics as a treatment for moderate psoriasis patients. This is consistent with a previous study of US dermatologists where about half of the participants reported biologic agents as their primary line of treatment.[11] However, these numbers are higher from previous surveys where only 5%–22.5% of moderate to severe psoriasis patients were reported to be using biologic therapy as their current treatment.[1,4] The difference may be originating from the larger sample sizes of other studies, different methodology, or the country-based differences in insurance coverage and treatment policies. Another possible explanation of such discrepancy may be drawn by the variability in defining moderate psoriasis; thus, some of the surveyed dermatologists may have included severe psoriasis patients when asked about their primary treatment for moderate psoriasis. The reported use of prescribing topical agents, systemic treatments, and biologics is consistent with the current guidelines for the treatment of psoriasis.[6,14] Although the concept of moderate psoriasis is defined by the AAD as a disease affecting ≥5% to <10% of BSA,[6] the use of this concept is still limited in guidelines context and among clinical trials. Similarly, many of the available clinical trials do not have predefined inclusion criteria limited to moderate psoriasis patients, rather than a range of severity, from mild to moderate or moderate to severe, in alignment with the FDA established regulations.[7,8,14,17-19]

This study has certain limitations that must be mentioned. As with any survey, there is a risk of response bias. Rating of knowledge and/or experience by oneself amid dermatologists may result in overestimation of genuine knowledge and even elevated self-reported utilization of resources of evidence. Another limitation is that prejudice in volunteerism may subsist as those who agreed to participate may acquire basically dissimilar knowledge and experience than those who did not participate.

## Conclusion

There is a pervasive lack of consensus regarding the definition of moderate psoriasis, with reported wide ranges among the commonly used severity tools in psoriasis patients. There is a need for developing, validating, and implementing a clinically-oriented definition of moderate plaque psoriasis for improving clinical outcomes and treatments choice in this patients’ group.
Declaration of patient consent
The authors certify that they have obtained all appropriate patient consent forms. In the form, the patients have given their consent for their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

References
1. Armstrong AW, Koning JW, Rowse S, Tan H, Mamolo C, Kaur M. Under-treatment of patients with moderate to severe psoriasis in the United States: Analysis of medication usage with health plan data. Dermatol Ther (Heidelb) 2017;7:97-109.
2. Soriano ER, Zazzetti F, Pereira IA, Cocco JM, Azevedo VF, Guerra G, et al. Physician-patient alignment in satisfaction with psoriatic arthritis treatment in Latin America. Clin Rheumatol 2020;39:1859-69.
3. Eissing L, Rudtke MA, Zander N, Augustin M. Barriers to guideline-compliant psoriasis care: Analyses and concepts. J Eur Acad Dermatol Venereol 2016;30:569-75.
4. Ogdie A, Nowell WB, Applegate E, Gavigan K, Venkatachalam S, de la Cruz M, et al. Patient perspectives on the pathway to psoriatic arthritis diagnosis: Results from a web-based survey of patients in the United States. BMC Rheumatol 2020;4:2.
5. Nast A, Mrowietz U, Kragballe K, de Jong EM, Puig L, Reich K, et al. Barriers to the prescription of systemic therapies for moderate-to-severe psoriasis—a multinational cross-sectional study. Arch Dermatol Res 2013;305:899-907.
6. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based conclusions. J Am Acad Dermatol 2011;65:137-74.
7. Papp KA, Armstrong AW, Reich K, Karunaratne M, Valdecantos W. Adalimumab efficacy in patients with psoriasis who received or did not respond to prior systemic therapy: A pooled post hoc analysis of results from three double-blind, placebo-controlled clinical trials. Am J Clin Dermatol 2016;17:79-86.
8. Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths CE, Nast A, et al. Definition of treatment goals for moderate to severe psoriasis: A European consensus. Arch Dermatol Res 2011;303:1-10.
9. Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med 2016;375:345-56.
10. Finlay AY, Reich K. Outcome assessment and treatment goals. Expert Rev Dermatol 2008;3(Suppl 1):S39-40.
11. Knuckles MLF, Levi E, Soung J. Defining and treating moderate plaque psoriasis: A dermatologist survey. J Dermatolog Treat 2018;29:658-63.
12. Emer JJ, Frankel A, Zeichner JA. A practical approach to monitoring patients on biological agents for the treatment of psoriasis. J Clin Aesthet Dermatol 2010;3:20-6.
13. West J, Ogston S, Foerster J. Safety and efficacy of methotrexate in psoriasis: A meta-analysis of published trials. PLoS One 2016;11:e0153740.
14. Papp K, Reich K, Leonardi CL, Kircik L, Chimenti S, Langley RG, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol 2015;73:37-49.
15. Strober B, Bagel J, Lebwohl M, Stein Gold L, Jackson JM, Chen R, et al. Efficacy and safety of apremilast in patients with moderate plaque psoriasis with lower BSA: Week 16 results from the UNVEIL study. J Drugs Dermatol 2017;16:801-8.
16. Van Voorhees A, Feldman SR, Koo J, Lebwohl MG, Menter A, Ritchlin C, et al. The Psoriasis and Psoriatic Arthritis Pocket Guide: Treatment Algorithms and Management Options. Portland (OR): National Psoriasis Foundation; 2016.
17. Reich K, Zschocke I, Bachelez H, de Jong EM, Gisondi P, Puig L, et al. Efficacy of a fixed combination of calcipotriol/betamethasone dipropionate topical gel in adult patients with mild to moderate psoriasis: Blinded interim analysis of a phase IV, multicenter, randomized, controlled, prospective study. J Eur Acad Dermatol Venereol 2015;29:1156-63.
18. Ports WC, Khan S, Lan S, Lamba M, Bolduc C, Bissonnette R, et al. A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. Br J Dermatol 2013;169:137-45.
19. Paul C, Cather J, Gooderham M, Poulin Y, Mrowietz U, Ferrandiz C, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: A phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol 2015;173:1387-99.